Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
9
Active, not recruiting, industry sponsors, Immunology and inflammation, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed251
9 trials
Showing 1 to 9, recently updated first.
- A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04929210 · 411 participants · Start Aug 30, 2021 · Primary completion Apr 1, 2027
Drug: Guselkumab; Placebo · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Chandler, Arizona; Mesa, Arizona · 240 sites in all
- A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Active, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06411249 · 302 participants · Start Jun 6, 2024 · Primary completion Jun 29, 2027
Drug: Belimumab (GSK1550188) · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Flagstaff, Arizona; Mesa, Arizona · 104 sites in all
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)Active, not recruiting
TakedaTakeda (TAK)
NCT06095128 · 60 participants (planned) · Start Jun 12, 2024 · Primary completion Jul 9, 2027
Drug: Vedolizumab; Tofacitinib · For: Ulcerative Colitis
Sites: Dothan, Alabama; Sun City, Arizona; Los Angeles, California · 45 sites in all
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseActive, not recruiting
TakedaTakeda (TAK)
NCT06045754 · 50 participants (planned) · Start Apr 18, 2024 · Primary completion Jun 28, 2027
Drug: Vedolizumab; Adalimumab and 2 more · For: Crohn's Disease
Sites: Dothan, Alabama; Sun City, Arizona; La Jolla, California · 48 sites in all
- A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque PsoriasisActive, not recruiting
Bausch Health Americas, Inc.Industry
NCT03987763 · 45 participants (planned) · Start Oct 22, 2019 · Primary completion Nov 2026
Drug: IDP-122 Lotion · For: Psoriasis
Sites: Fountain Valley, California; Thousand Oaks, California; Doral, Florida · 9 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06864026 · 200 participants (planned) · Start Mar 6, 2025 · Primary completion Aug 2027
Drug: Tirzepatide · For: Psoriatic Arthritis; Overweight or Obesity
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 55 sites in all
- A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical PracticeActive, not recruiting
Eisai Korea Inc.Eisai
NCT06964113 · 94 participants (planned) · Start Jun 11, 2025 · Primary completion Nov 30, 2027
Drug: Filgotinib Maleate · For: Ulcerative Colitis
Sites: Busan, South Korea; Daegu, South Korea; Daejeon, South Korea · 19 sites in all
- A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic DermatitisActive, not recruiting
SanofiSanofi (SNY)
NCT05983068 · 48 participants (planned) · Start Feb 22, 2024 · Primary completion Apr 29, 2027
Drug: dupilumab · For: Dermatitis Atopic
Sites: Denver, Colorado; St Louis, Missouri; New York, New York · 4 sites in all
- An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsActive, not recruiting
Bausch Health Americas, Inc.Industry
NCT03240809 · 2 participants · Start Jan 24, 2020 · Primary completion Dec 2028
Drug: Brodalumab; Brodalumab · For: Psoriasis
Sites: San Diego, California; Miami, Florida; Henderson, Nevada · 5 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.